Trusted Osteoarthritis Drug Fails Major Knee Pain Trial

For years diacerein carried the quiet promise of a plant-derived fix for aching knees — a compound drawn from rhubarb and aloe vera that targets inflammation rather than simply masking pain. The hope was real. So were the expectations.

But a large international study led by the University of Tasmania’s Menzies Institute for Medical Research has delivered a clear, disappointing answer: diacerein did not reduce pain, improve function, or shrink the inflammatory swelling in people with knee osteoarthritis, even among those who had visible joint inflammation.

Called the DICKENS trial and headed by Associate Professor Dawn Aitken, the study focused on a subgroup of patients thought most likely to benefit. The logic was straightforward. If an anti-inflammatory drug were going to help, these were the people who should show an effect. They did not.

The findings landed in JAMA Internal Medicine, a signal that the research was held to a high bar. Publishing there doesn’t soften the blow; it amplifies the import. Clinicians and researchers now know, with stronger evidence, that this particular route—diacerein for inflamed knee osteoarthritis—does not deliver the clinical relief many had hoped for.

Why does this matter? Osteoarthritis is not a niche problem. One in five Australians over 45 live with it, and globally the condition drives pain, disability, and a rising tide of joint replacements. Yet medication options that reliably ease chronic osteoarthritis pain are scant. When a candidate drug fails a large trial, it narrows the field and forces scientists back to the drawing board.

That said, the story isn’t only about a setback. Trials that don’t show benefit are as important as those that do; negative results stop ineffective treatments from gaining ground and steer funding and attention toward more promising approaches. Associate Professor Aitken stresses that researchers are still testing other compounds and strategies that might one day help people with long-term joint pain.

Meanwhile, practical care remains the mainstay. Education, targeted exercise, weight management and psychological support are the treatments backed by the strongest evidence for improving quality of life in osteoarthritis. Medications can play a role, but they rarely act alone.

If you are taking diacerein now, don’t make changes on your own. Talk with your treating doctor before stopping or switching therapies. Science advances in fits and starts, and every trial—positive or negative—helps map a clearer path forward for people living with chronic joint pain.